Cardiac tumors laboratory tests: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiac tumors}} | {{Cardiac tumors}} | ||
{{CMG}}; {{AE}} {{Dj}} | |||
==Overview== | |||
==Laboratory Findings== | |||
===Blood Investigations=== | |||
*Some patients with cardiac tumors may have anemia, less commonly thrombocytopenia, increases in sedimentation rate, serum C-reactive protein level, or globulin level. These are nonspecific diagnostic anomalies. | |||
*Antimyolemmal antibodies could also be elevated. Antimyolemmal antibodies are significantly more prevalent in chronic pericardial effusion, perimyocarditis, and dilated cardiomyopathy patients than healthy controls. | |||
*Antiendothelial antibodies of the IgG type are detected in 86 percent of atrial myxoma patients. Endothelial cells are activated by Antiendothelial antibodies, leading to enhanced leukocyte adhesion, clotting activation, and vessel thrombosis. | |||
==References== | ==References== | ||
Revision as of 23:43, 14 May 2022
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors laboratory tests On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors laboratory tests |
|
Risk calculators and risk factors for Cardiac tumors laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Dj
Overview
Laboratory Findings
Blood Investigations
- Some patients with cardiac tumors may have anemia, less commonly thrombocytopenia, increases in sedimentation rate, serum C-reactive protein level, or globulin level. These are nonspecific diagnostic anomalies.
- Antimyolemmal antibodies could also be elevated. Antimyolemmal antibodies are significantly more prevalent in chronic pericardial effusion, perimyocarditis, and dilated cardiomyopathy patients than healthy controls.
- Antiendothelial antibodies of the IgG type are detected in 86 percent of atrial myxoma patients. Endothelial cells are activated by Antiendothelial antibodies, leading to enhanced leukocyte adhesion, clotting activation, and vessel thrombosis.